A citation-based method for searching scientific literature

Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Domenico Milardi, Laura De Marinis, Alfredo Pontecorvi. Trends Endocrinol Metab 2022
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Raffaele Ratta, Annalisa Guida, Florian Scotté, Yann Neuzillet, Asmahane Benmaziane Teillet, Thierry Lebret, Philippe Beuzeboc. Prostate Cancer Prostatic Dis 2020
21
50



Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Lei Wang, Changyong Yang, Chengying Xie, Jiahua Jiang, Mingzhao Gao, Li Fu, Yun Li, Xubin Bao, Haoyu Fu, Liguang Lou. Cancer Sci 2019
29
50

[68Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma.
Pengjun Zhang, Zhenyu Zhao, Lulu Zhang, Wenyu Wu, Yuping Xu, Donghui Pan, Feng Wang, Min Yang. Nucl Med Biol 2019
5
50

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.
Geoffrey Kim, Gwynn Ison, Amy E McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip,[...]. Clin Cancer Res 2015
330
50

Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Christian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, L Rhoda Molife, Jan H M Schellens, Jacques De Grève, Luc Dirix, Peter Grundtvig-Sørensen, Guy Jerusalem, Karin Leunen,[...]. Clin Pharmacokinet 2019
7
50

Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Jing Luo, Xinchi Dai, Hua Hu, Jie Chen, Lujun Zhao, Changyong Yang, Jifeng Sun, Lianmin Zhang, Qian Wang, Shilei Xu,[...]. J Cancer Res Clin Oncol 2020
13
50

Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.
Mi Young Kim, Tong Zhang, W Lee Kraus. Genes Dev 2005
611
50

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study.
Jonathan Strosberg, Pamela L Kunz, Andrew Hendifar, James Yao, David Bushnell, Matthew H Kulke, Richard P Baum, Martyn Caplin, Philippe Ruszniewski, Ebrahim Delpassand,[...]. Eur J Nucl Med Mol Imaging 2020
43
50

Role of poly(ADP-ribose) formation in DNA repair.
M S Satoh, T Lindahl. Nature 1992
917
50

Treatment sequence in patients with neuroendocrine tumours: a nationwide multicentre, observational analysis of the Swiss neuroendocrine tumour registry.
Attila Kollar, Lukas Bütikofer, Adrian Ochsenbein, Christoph Stettler, Roman Trepp. Swiss Med Wkly 2020
7
50

Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.
Christian Boehler, Laurent R Gauthier, Oliver Mortusewicz, Denis S Biard, Jean-Michel Saliou, Anne Bresson, Sarah Sanglier-Cianferani, Susan Smith, Valérie Schreiber, François Boussin,[...]. Proc Natl Acad Sci U S A 2011
190
50

Single-Strand Break End Resection in Genome Integrity: Mechanism and Regulation by APE2.
Md Akram Hossain, Yunfeng Lin, Shan Yan. Int J Mol Sci 2018
32
50

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
50

Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks.
T Lindahl, M S Satoh, G G Poirier, A Klungland. Trends Biochem Sci 1995
522
50

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Arnab Ray Chaudhuri, André Nussenzweig. Nat Rev Mol Cell Biol 2017
603
50

An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.
Ning Li, Hualei Bu, Jihong Liu, Jianqing Zhu, Qi Zhou, Li Wang, Rutie Yin, Xiaohua Wu, Shuzhong Yao, Kangsheng Gu,[...]. Clin Cancer Res 2021
12
50

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
352
50

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
Jonathan Strosberg, Ghassan El-Haddad, Edward Wolin, Andrew Hendifar, James Yao, Beth Chasen, Erik Mittra, Pamela L Kunz, Matthew H Kulke, Heather Jacene,[...]. N Engl J Med 2017
50

Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja A Kühl, Vikas Prasad, Winfried Brenner, Eva J Koziolek. J Nucl Med 2021
2
50

Overexpression of human poly(ADP-ribose) polymerase in transfected hamster cells leads to increased poly(ADP-ribosyl)ation and cellular sensitization to gamma irradiation.
L Van Gool, R Meyer, E Tobiasch, C Cziepluch, J C Jauniaux, A Mincheva, P Lichter, G G Poirier, A Bürkle, J H Küpper. Eur J Biochem 1997
47
50

Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).
John K Ramage, A Ahmed, J Ardill, N Bax, D J Breen, M E Caplin, P Corrie, J Davar, A H Davies, V Lewington,[...]. Gut 2012
355
50

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.
Anders Sundin, Rudolf Arnold, Eric Baudin, Jaroslaw B Cwikla, Barbro Eriksson, Stefano Fanti, Nicola Fazio, Francesco Giammarile, Rodney J Hicks, Andreas Kjaer,[...]. Neuroendocrinology 2017
170
50

Gastroenteropancreatic neuroendocrine neoplasms and inflammation: A complex cross-talk with relevant clinical implications.
Giovanni Vitale, Silvia Carra, Francesco Ferraù, Elia Guadagno, Antongiulio Faggiano, Annamaria Colao. Crit Rev Oncol Hematol 2020
6
50

Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
Eitan Mirvis, Christos Toumpanakis, Dalvinder Mandair, Gopinath Gnanasegaran, Martyn Caplin, Shaunak Navalkissoor. Lung Cancer 2020
6
50

DNA repair, genome stability and cancer: a historical perspective.
Penny A Jeggo, Laurence H Pearl, Antony M Carr. Nat Rev Cancer 2016
369
50

Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Annarita Ianniello, Maddalena Sansovini, Stefano Severi, Silvia Nicolini, Chiara Maria Grana, Katrin Massri, Alberto Bongiovanni, Lorenzo Antonuzzo, Valentina Di Iorio, Anna Sarnelli,[...]. Eur J Nucl Med Mol Imaging 2016
49
50

Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Ye Han, Mei-Kuang Chen, Hung-Ling Wang, Jennifer L Hsu, Chia-Wei Li, Yu-Yi Chu, Chun-Xiao Liu, Lei Nie, Li-Chuan Chan, Clinton Yam,[...]. Am J Cancer Res 2019
19
50

Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Monica Mangoni, Mariangela Sottili, Giulia Salvatore, Icro Meattini, Isacco Desideri, Daniela Greto, Mauro Loi, Carlotta Becherini, Pietro Garlatti, Camilla Delli Paoli,[...]. Radiat Res 2018
11
50

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
James C Yao, Manal Hassan, Alexandria Phan, Cecile Dagohoy, Colleen Leary, Jeannette E Mares, Eddie K Abdalla, Jason B Fleming, Jean-Nicolas Vauthey, Asif Rashid,[...]. J Clin Oncol 2008
50

Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.
Dixita Ishani Viswanath, Hsuan-Chen Liu, David P Huston, Corrine Ying Xuan Chua, Alessandro Grattoni. Biomaterials 2022
3
50

Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.
Claudia Ortega, Rebecca K S Wong, Josh Schaefferkoetter, Patrick Veit-Haibach, Sten Myrehaug, Rosalyn Juergens, David Laidley, Reut Anconina, Amy Liu, Ur Metser. J Nucl Med 2021
15
50


Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Arvind Dasari, Chan Shen, Daniel Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Tina Shih, James C Yao. JAMA Oncol 2017
50


Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.
Julie Nonnekens, Melissa van Kranenburg, Cecile E M T Beerens, Mustafa Suker, Michael Doukas, Casper H J van Eijck, Marion de Jong, Dik C van Gent. Theranostics 2016
67
50


The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET.
Anna Zemczak, Paweł Gut, Dariusz Pawlak, Maciej Kołodziej, Leszek Królicki, Beata Kos-Kudła, Marek Ruchała, Grzegorz Kamiński, Jolanta Kunikowska. Int J Endocrinol 2021
3
50




PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Emily Nizialek, Emmanuel S Antonarakis. Cancer Manag Res 2020
29
50

Adrenal insufficiency due to bilateral adrenal metastases - A systematic review and meta-analysis.
Philippa H Tallis, R Louise Rushworth, David J Torpy, Henrik Falhammar. Heliyon 2019
16
50

Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis.
Leonie H A Broersen, Alberto M Pereira, Jens Otto L Jørgensen, Olaf M Dekkers. J Clin Endocrinol Metab 2015
178
50

The diagnosis and treatment of adrenal insufficiency during childhood and adolescence.
Julie Park, Mohammed Didi, Joanne Blair. Arch Dis Child 2016
29
50

Normal overall mortality rate in Addison's disease, but young patients are at risk of premature death.
Martina M Erichsen, Kristian Løvås, Kristian J Fougner, Johan Svartberg, Erik R Hauge, Jens Bollerslev, Jens P Berg, Bjarne Mella, Eystein S Husebye. Eur J Endocrinol 2009
151
50

Management of adolescents with congenital adrenal hyperplasia.
Deborah P Merke, Dix P Poppas. Lancet Diabetes Endocrinol 2013
48
50

Clues for early detection of autoimmune Addison's disease - myths and realities.
Å B Saevik, A-K Åkerman, K Grønning, I Nermoen, S F Valland, T E Finnes, M Isaksson, P Dahlqvist, R Bergthorsdottir, O Ekwall,[...]. J Intern Med 2018
17
50

Daily adjustment of glucocorticoids by patients with adrenal insufficiency.
Christof Schöfl, Bernhard Mayr, Nicole Maison, Felix Beuschlein, Gesine Meyer, Klaus Badenhoop, Tina Kienitz, Marcus Quinkler. Clin Endocrinol (Oxf) 2019
9
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.